<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303992</url>
  </required_header>
  <id_info>
    <org_study_id>037517</org_study_id>
    <secondary_id>UCSF-037517</secondary_id>
    <secondary_id>UCSF-H6961-24269-02A</secondary_id>
    <nct_id>NCT00303992</nct_id>
    <nct_alias>NCT00145821</nct_alias>
  </id_info>
  <brief_title>Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer</brief_title>
  <official_title>Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      irinotecan, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving trastuzumab together with irinotecan may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving trastuzumab together with irinotecan&#xD;
      works in treating patients with HER2/neu positive metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the overall objective response-rate (partial and complete) and stable disease&#xD;
           rate in patients with HER2/neu positive metastatic breast cancer treated with the&#xD;
           combination of irinotecan hydrochloride and trastuzumab (Herceptin®) after prior first-&#xD;
           or second-line therapy with trastuzumab combined with other chemotherapeutic agents.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicities of this combination regimen.&#xD;
&#xD;
        -  Determine the duration of response and time to disease progression in patients treated&#xD;
           with this combination.&#xD;
&#xD;
        -  Document development of brain metastases or progression of known metastases in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, 15,&#xD;
      and 22 and irinotecan hydrochloride IV over 30-60 minutes on days 1, 8, and 15. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">November 16, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall objective response rate (partial and complete responses)</measure>
    <time_frame>up to 20 months post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable disease rate</measure>
    <time_frame>up to 20 months post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 20 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 20 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>up to 20 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of brain metastases or progression of known metastases on this treatment</measure>
    <time_frame>up to 20 months post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab and Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>Trastuzumab and Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Trastuzumab and Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic breast carcinoma&#xD;
&#xD;
          -  Received 1-3 prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
               -  Documented progressive disease&#xD;
&#xD;
               -  Repeated courses of the same chemotherapy agent alone or in combination are&#xD;
                  considered a single regimen&#xD;
&#xD;
               -  Prior trastuzumab (Herceptin®) alone or with chemotherapy allowed&#xD;
&#xD;
                    -  Other biologic agents are not considered a chemotherapy regimen&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Patients with bone-only disease who are evaluable by tumor markers (e.g., CA15-3,&#xD;
                  CEA, or CA27.29) are eligible&#xD;
&#xD;
                    -  Patients must have prior evidence of correlation of disease activity with&#xD;
                       changes in tumor marker level&#xD;
&#xD;
          -  Confirmation of HER2/neu status by a positive test for gene amplification by&#xD;
             fluorescence in situ hybridization or 3+ by immunohistochemistry&#xD;
&#xD;
          -  Brain metastases allowed if the following criteria are met:&#xD;
&#xD;
               -  Brain metastases were previously treated and are currently stable as documented&#xD;
                  by head CT scan with contrast or MRI within 4 weeks of study entry&#xD;
&#xD;
                    -  Patients with existing brain metastases should have stability documented by&#xD;
                       prior imaging ≥ 8 weeks before the baseline scan&#xD;
&#xD;
          -  Hormone-receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  Documented ejection fraction ≥ 45% by MUGA scan or echocardiogram within 1 month of&#xD;
             study entry&#xD;
&#xD;
          -  Total bilirubin &lt; 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST &lt; 3 times ULN (5 times ULN if due to liver involvement)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  No history of serious adverse events related to trastuzumab&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No severe, concurrent illness that would prevent compliance with study protocol&#xD;
&#xD;
          -  No chronic severe diarrheal illness&#xD;
&#xD;
          -  No history of Gilbert's disease or known deficiency in glucuronidation&#xD;
&#xD;
          -  No recent or current history of alcoholism or acute viral hepatitis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No chemotherapy or hormonal therapy within the past 2 weeks&#xD;
&#xD;
          -  Prior or concurrent bisphosphonates allowed&#xD;
&#xD;
          -  No prior irinotecan (other camptothecins allowed)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No ongoing treatment with any other investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope S. Rugo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judy M. Cheng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-1710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

